Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies
Open Access

Possible Alterations in Appetite-related Molecules After the Elimination of Hepatitis C Virus

YOSHIHIRO SHIMONO, HIRAYUKI ENOMOTO, NOBUHIRO AIZAWA, TOMOYUKI TAKASHIMA, NAOTO IKEDA, YUKIHISA YURI, AOI FUJIWARA, KOHEI YOSHIHARA, RYOTA YOSHIOKA, SHOKI KAWATA, SHOGO OTA, RYOTA NAKANO, HIDEYUKI SHIOMI, TAKASHI NISHIMURA and HIROKO IIJIMA
In Vivo May 2022, 36 (3) 1491-1496; DOI: https://doi.org/10.21873/invivo.12856
YOSHIHIRO SHIMONO
1Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan;
2Wakakusa-Daiichi Hospital, Higashiosaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIRAYUKI ENOMOTO
1Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: enomoto@hyo-med.ac.jp
NOBUHIRO AIZAWA
1Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOMOYUKI TAKASHIMA
1Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NAOTO IKEDA
1Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUKIHISA YURI
1Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AOI FUJIWARA
1Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOHEI YOSHIHARA
1Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RYOTA YOSHIOKA
1Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHOKI KAWATA
1Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHOGO OTA
1Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RYOTA NAKANO
1Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIDEYUKI SHIOMI
1Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKASHI NISHIMURA
1Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROKO IIJIMA
1Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Recent advances in antiviral treatment have achieved a sustained viral response (SVR) in over 95% of hepatitis C virus (HCV) infections. HCV elimination is suggested to improve several lifestyle-related factors; however, few studies have focused on dietary habit-/appetite-related factors. Patients and Methods: HCV-infected patients who received Daclatasvir/Asnaprevir (DCV/ASV) therapy were enrolled, and the changes in appetite-related molecules after antiviral therapy were assessed with a multiple cytokine-measuring system. Results: Among 119 HCV-infected patients who received DCV/ASV treatment, 104 (87.3%) achieved an SVR. In the SVR group, DCV/ASV treatment improved several liver-related variables at 24 weeks after the completion of therapy. In patients with an SVR, the values of glucagon-like peptide 1 (GLP-1) and leptin were significantly increased at 24 weeks after completing direct-acting antiviral therapy. However, no significant change was observed in non-SVR patients, regardless of the receipt of direct-acting antiviral treatment. Conclusion: Gastrointestinal hormones related to the dietary habit and/or appetite may be influenced by HCV elimination.

  • Chronic hepatitis C
  • direct acting antiviral
  • sustained viral response
  • appetite-related hormones

Infection with hepatitis C virus (HCV) is a major cause of chronic liver disease (CLD). Recent advances in antiviral treatment with direct-acting antivirals (DAAs) have achieved a sustained viral response (SVR) in over 95% (around 98%-99%) of HCV-infected patients (1-3). Based on this highly successful ratio of HCV elimination, various effects after SVR achievement have been reported, as HCV elimination is known to affect not only the liver function but also its related metabolism (4, 5). In addition, HCV elimination is suggested to improve several lifestyle-related factors, including the activities of daily living (ADL) and quality of life (QOL) (6, 7). Regarding lifestyle-related factors, the dietary habit is particularly important, as is exercise. However, few studies have focused on dietary habit-/appetite-related factors. Such data may provide new information regarding the effects of an SVR on HCV-infected patients.

Interferon (IFN) therapy has been suggested to influence the patient condition, in not only those with an SVR but even those without an SVR (8-10). Thus, the effects of HCV elimination after DAA therapy should be precisely clarified by a comparison with a control group that did not achieve an SVR. However, because of the extremely low ratio of non-SVR patients with current DAA therapies, such a comparison has been difficult to conduct.

In Japan, Daclatasvir/Asnaprevir (DCV/ASV) combination therapy was first approved as IFN-free therapy for hepatitis C in 2014. The SVR ratio with DCV/ASV therapy is around 85-89% (11, 12), so clinical data from a moderate number of patients without an SVR (non-SVR patients after DAA therapy) are available.

In the current study, we preliminarily evaluated the changes in metabolism- and appetite-related molecules in patients with and without an SVR after the same DAA therapy.

Patients and Methods

Patients and DAA therapy. Among the HCV-infected patients who received DCV/ASV treatment in our Department, we assessed those whose preserved sera could be used for the current study. An SVR was defined when serum HCV RNA was undetectable at 24 weeks after the completion of the treatment. Non-SVR was defined when serum HCV RNA was still detected within 24 weeks after the termination of the DCV/ASV treatment.

Measurement of metabolic molecules. To measure multiple hormones, we used the BioPlex® protein assay system (Bio-Rad, Hercules, CA, USA) (13, 14). We selected eight appetite-related gastrointestinal hormones, including total amylin, glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1), ghrelin, insulin, leptin, pancreatic polypeptide (PP) and peptide YY (PYY) from the MILLIPLEX™ MAP Human Metabolic Hormone Panel (Millipore, Billerica, MA, USA) and measured these hormones according to the manufacturer’s instructions (15-18). We used 200 μl of preserved sera per sample and directly applied it to the system for measuring multiple hormones simultaneously. Among those hormones, the results of amylin, ghrelin and PYY were excluded from the analyses, as more than half of the samples were shown to be below the quantification limits (amylin, 13 pg/ml; ghrelin, 13 pg/ml; PYY, 28 pg/ml), and median values could not be determined. Thus, we used the data of the remaining five hormones.

We compared the values of the hormones at the initiation of the DAA therapy and at 24 weeks after the completion of the therapy. The hormones were measured both in 15 non-SVR (control) patients and in 15 patients with an SVR. We screened for SVR patients whose preserved sera were available, and selected 15 SVR patients who have similar clinical characteristics to the non-SVR patients regarding their age and the degree of liver fibrosis (histological fibrosis stage or platelet count). The FIB-4 index, which is a highly used biomarker for liver fibrosis, was determined based on the following formula: FIB-4=Age [years]×AST [U/l]/(platelets [109/l]×(ALT [U/l])1/2) (19).

The current study was conducted with the approval by the ethics committee of the institutional review board (Nos. 1831 and 3321). Statistical analyses. Numerical variables were shown as the median (interquartile range), and the differences between two groups were evaluated using the Mann-Whitney U-test. Differences in the frequency of categorized variables between two groups were evaluated using Fisher’s exact test. The changes in the values of appetite-related hormones between the pre- and post-treatment phases were assessed using Wilcoxon’s signed-rank test. A p-value less than 0.05 was defined as statistically significant.

Results

Antiviral effects of DCV/ASV therapy. Among a total of 119 HCV-infected patients who received DCV/ASV treatment, 104 (87.3%) achieved an SVR, and the remaining 15 were classified as non-SVR patients. The basic characteristics of patients were not significantly different between the SVR and non-SVR groups (Table I). In the SVR group, DCV/ASV treatment improved several liver-related variables at 24 weeks after the completion of therapy (Figure 1).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Basic clinical data of patients who received daclatasvir and asunaprevir combination therapy.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Changes in the liver-related variables after HCV elimination. Several liver-related variables at the initiation of the DAA therapy and at 24 weeks after the completion of the therapy in patients with a sustained viral response (N=104) were compared. Box plots: 10th percentile, 25th percentile; median, 75th percentile and 90th percentile. AST: Aspartate aminotransferase; ALT: alanine aminotransferase; γ-GTP: γ-glutamyl transpeptidase; ALP: alkaline phosphatase.

Changes in metabolic hormones after DCV/ASV therapy. To assess the changes in metabolism- and appetite-related hormones after HCV elimination, we selected 15 SVR patients who have similar clinical characteristics to the 15 non-SVR patients in relation to their age and degree of liver fibrosis. No significant difference was found in the variables, including the FIB-4 index, a major biomarker for liver fibrosis (19) (Table II). As described in the “Patients and Methods” section, we analyzed the data of the five appetite-related gastrointestinal hormones, including GIP, GLP-1, insulin, leptin and PP. In patients with an SVR, the values of GLP-1 and leptin were significantly increased at 24 weeks after the completion of DAA therapy (Table III). However, no significant changes were observed in non-SVR patients, regardless of the receipt of DAA treatment (Table IV).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Basic clinical data of patients who received daclatasvir and asunaprevir combination therapy.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Changes in the appetite-related hormones in patients with an SVR.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table IV.

Changes in the appetite-related hormones in patients without an SVR.

Discussion

Because of advances in the treatment of viral hepatitis, a nationwide survey showed that the rate of hepatitis virus-associated liver cirrhosis, particularly HCV-related cirrhosis decreased in Japan (20). HCV elimination is known to improve various physical and mental statuses, including changes in the metabolism of patients (4-7). Using the multiple cytokine assay system, we simultaneously measured several molecules with a small volume of sera (200 μl per sample) and explored whether or not appetite-related hormones were affected by HCV elimination.

‘Lifestyle’ covers various aspects, including the physical exercise and dietary habits. Recently, sarcopenia (muscle volume loss) has been recognized as a clinically important factor, and the importance of exercise is being increasingly recognized (21-24). However, factors associated with the dietary habit are less frequently assessed, and in particular, changes in appetite-related hormones in response to HCV elimination have barely been examined. Unlike non-SVR patients, GLP-1 and leptin levels were increased in those who achieved an SVR in our study. Previous studies have suggested that various metabolic functions, including the glucose metabolism, are altered in HCV-eliminated patients (4, 5). Our results suggest that changes in appetite-related hormones may be involved in the changes to the metabolism in HCV-eliminated patients.

The current study is unique in that we investigated the changes in appetite-related hormones in response to HCV elimination. In addition, data from patients who did not achieve an SVR after DAA therapy were used as the control set. Unlike IFN therapy (8-10), the failure of antiviral therapy was suggested to have relatively little influence on patients who received DAA therapy (Table IV). Recently, a study that analyzed patients with non-SVR was reported (25); however, the results were obtained from patients who received various types of DAA therapies. Given the recently reported high SVR rate (98-99%), comparing data between SVR and non-SVR patients who receive the same treatment protocol is not easy and is specific to this study. To our knowledge, the changes in appetite-related hormones in response to HCV elimination have not been previously reported, though ‘eating habits’ are quite important for human health (26). Thus, our data would provide new information regarding the effects of an SVR on HCV-infected patients.

Several limitations associated with the present study warrant mention. First, this was a retrospective study using preserved sera. Second, based on the fact that 10-15% of patients failed to achieve an SVR following DCV/ASV therapy, we used these patients as non-SVR cases; however, this number was still relatively small. Third, we did not clarify the clinical impact of the changes in appetite-related hormones, such as the influence on the appetite, dietary habit and body weight, although a recent report suggested that an SVR cause a gain in body weight (27). Thus, the present study is a preliminary one, and our results should be evaluated in another study with a larger number of patients.

In summary, this is the first report regarding the changes in gastrointestinal hormones in response to HCV elimination. Our results suggest that some hormones that are related to the dietary habit and/or appetite may be influenced by HCV elimination following DAA treatment.

Acknowledgements

We are grateful to Kanazawa N, Kasuya Y, Inui S, Fujii S, Kido H, Shimoji Y and Minemoto K (Hyogo College of Medicine) for their technical and secretarial assistance.

Footnotes

  • Authors’ Contributions

    YS proposed the study concept, collected the data, and analyzed the data; HE designed the study, analyzed the data, and wrote the manuscript. NA, TT, NI, YY, AF, KY, RY, SK, SO, RN, HS, and TN collected and interpreted the data; HI collected the data and supervised the study. All of the Authors reviewed and edited the manuscript and approved the final version of the manuscript.

  • Conflicts of Interest

    The Authors declare no conflicts of interest in association with the present study.

  • Received February 25, 2022.
  • Revision received March 21, 2022.
  • Accepted April 1, 2022.
  • Copyright © 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

References

  1. ↵
    Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology: Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update. Hepatol Res 50(7): 791-816, 2020. PMID: 32343477. DOI: 10.1111/hepr.13503
    OpenUrlCrossRefPubMed
  2. European Association for the Study of the Liver, Clinical Practice Guidelines Panel: Chair, EASL Governing Board representative and Panel members: EASL recommendations on treatment of hepatitis C: Final update of the series*. J Hepatol 73(5): 1170-1218, 2020. PMID: 32956768. DOI: 10.1016/.jhep. 2020.08.018
    OpenUrlCrossRefPubMed
  3. ↵
    1. Ghany MG,
    2. Morgan TR
    and AASLD-IDSA Hepatitis C Guidance Panel: Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology 71(2): 686-721, 2020. PMID: 31816111. DOI: 10.1002/hep.31060
    OpenUrlCrossRefPubMed
  4. ↵
    1. Inoue T,
    2. Goto T,
    3. Iio E,
    4. Matsunami K,
    5. Fujiwara K,
    6. Shinkai N,
    7. Matsuura K,
    8. Matsui T,
    9. Nojiri S and
    10. Tanaka Y
    : Changes in serum lipid profiles caused by three regimens of interferon-free direct-acting antivirals for patients infected with hepatitis C virus. Hepatol Res 48(3): E203-E212, 2018. PMID: 28834042. DOI: 10.1111/hepr.12970
    OpenUrlCrossRefPubMed
  5. ↵
    1. Mazzaro C,
    2. Quartuccio L,
    3. Adinolfi LE,
    4. Roccatello D,
    5. Pozzato G,
    6. Nevola R,
    7. Tonizzo M,
    8. Gitto S,
    9. Andreone P and
    10. Gattei V
    : A review on extrahepatic manifestations of chronic hepatitis C virus infection and the impact of direct-acting antiviral therapy. Viruses 13(11): 2249, 2021. PMID: 34835054. DOI: 10.3390/v13112249
    OpenUrlCrossRefPubMed
  6. ↵
    1. Younossi ZM,
    2. Stepanova M,
    3. Racila A,
    4. Afendy A,
    5. Lawitz EJ,
    6. Schwabe C,
    7. Ruane PJ,
    8. Lalezari J,
    9. Reddy KR,
    10. Jacobson IM,
    11. Muir AJ,
    12. Gaggar A,
    13. Myers RP,
    14. Younossi I and
    15. Nader F
    : Long-term benefits of sustained virologic response for patient-reported outcomes in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 18(2): 468-476.e11, 2020. PMID: 31376493. DOI: 10.1016/j.cgh.2019.07.047
    OpenUrlCrossRefPubMed
  7. ↵
    1. Evon DM,
    2. Kim HP,
    3. Edwards A,
    4. Carda-Auten J,
    5. Reeve BB,
    6. Golin CE and
    7. Fried MW
    : “If i get cured, my whole quality of life will change”: Patients’ anticipated and actualized benefits following cure from chronic hepatitis C. Dig Dis Sci 67(1): 100-120, 2022. PMID: 33528686. DOI: 10.1007/s10620-021-06829-2
    OpenUrlCrossRefPubMed
  8. ↵
    1. Shiratori Y,
    2. Imazeki F,
    3. Moriyama M,
    4. Yano M,
    5. Arakawa Y,
    6. Yokosuka O,
    7. Kuroki T,
    8. Nishiguchi S,
    9. Sata M,
    10. Yamada G,
    11. Fujiyama S,
    12. Yoshida H and
    13. Omata M
    : Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 132(7): 517-524, 2000. PMID: 10744587. DOI: 10.7326/0003-4819-132-7-200004040-00002
    OpenUrlCrossRefPubMed
    1. Nishiguchi S,
    2. Kuroki T,
    3. Nakatani S,
    4. Morimoto H,
    5. Takeda T,
    6. Nakajima S,
    7. Shiomi S,
    8. Seki S,
    9. Kobayashi K and
    10. Otani S
    : Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346(8982): 1051-1055, 1995. PMID: 7564784. DOI: 10.1016/s0140-6736(95)91739-x
    OpenUrlCrossRefPubMed
  9. ↵
    1. Kasahara A,
    2. Hayashi N,
    3. Mochizuki K,
    4. Takayanagi M,
    5. Yoshioka K,
    6. Kakumu S,
    7. Iijima A,
    8. Urushihara A,
    9. Kiyosawa K,
    10. Okuda M,
    11. Hino K and
    12. Okita K
    : Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 27(5): 1394-1402, 1998. PMID: 9581697. DOI: 10.1002/hep.510270529
    OpenUrlCrossRefPubMed
  10. ↵
    1. Kumada H,
    2. Suzuki Y,
    3. Ikeda K,
    4. Toyota J,
    5. Karino Y,
    6. Chayama K,
    7. Kawakami Y,
    8. Ido A,
    9. Yamamoto K,
    10. Takaguchi K,
    11. Izumi N,
    12. Koike K,
    13. Takehara T,
    14. Kawada N,
    15. Sata M,
    16. Miyagoshi H,
    17. Eley T,
    18. McPhee F,
    19. Damokosh A,
    20. Ishikawa H and
    21. Hughes E
    : Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 59(6): 2083-2091, 2014. PMID: 24604476. DOI: 10.1002/hep.27113
    OpenUrlCrossRefPubMed
  11. ↵
    1. Wang HL,
    2. Lu X,
    3. Yang X and
    4. Xu N
    : Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis. J Gastroenterol Hepatol 32(1): 45-52, 2017. PMID: 27597318. DOI: 10.1111/jgh.13587
    OpenUrlCrossRefPubMed
  12. ↵
    1. Wang CC,
    2. Tseng KC,
    3. Tzeng IS and
    4. Kao JH
    : The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma. J Formos Med Assoc 120(3): 965-973, 2021. PMID: 33129621. DOI: 10.1016/j.jfma.2020.10.015
    OpenUrlCrossRefPubMed
  13. ↵
    1. Izbicka E,
    2. Streeper RT and
    3. Louden C
    : Adaptive membrane fluidity modulation: a feedback regulated homeostatic system and target for pharmacological intervention. In Vivo 35(6): 3073-3095, 2021. PMID: 34697139. DOI: 10.21873/invivo.12603
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Huml M,
    2. Kobr J,
    3. Siala K,
    4. Varvařovská J,
    5. Pomahačová R,
    6. Karlíková M and
    7. Sýkora J
    : Gut peptide hormones and pediatric type 1 diabetes mellitus. Physiol Res 60(4): 647-658, 2011. PMID: 21574763. DOI: 10.33549/physiolres.931995
    OpenUrlCrossRefPubMed
    1. Yap TW,
    2. Leow AH,
    3. Azmi AN,
    4. Francois F,
    5. Perez-Perez GI,
    6. Blaser MJ,
    7. Poh BH,
    8. Loke MF,
    9. Goh KL and
    10. Vadivelu J
    : Changes in metabolic hormones in Malaysian young adults following Helicobacter pylori eradication. PLoS One 10(8): e0135771, 2015. PMID: 26291794. DOI: 10.1371/journal.pone.0135771
    OpenUrlCrossRefPubMed
    1. Belinova L,
    2. Kahleova H,
    3. Malinska H,
    4. Topolcan O,
    5. Windrichova J,
    6. Oliyarnyk O,
    7. Kazdova L,
    8. Hill M and
    9. Pelikanova T
    : The effect of meal frequency in a reduced-energy regimen on the gastrointestinal and appetite hormones in patients with type 2 diabetes: A randomised crossover study. PLoS One 12(4): e0174820, 2017. PMID: 28369078. DOI: 10.1371/journal.pone.0174820
    OpenUrlCrossRefPubMed
  15. ↵
    1. Martinez EE,
    2. Panciotti C,
    3. Pereira LM,
    4. Kellogg MD,
    5. Stylopoulos N and
    6. Mehta NM
    : Gastrointestinal hormone profiles associated with enteral nutrition tolerance and gastric emptying in pediatric critical illness: a pilot study. JPEN J Parenter Enteral Nutr 44(3): 472-480, 2020. PMID: 31304610. DOI: 10.1002/jpen.1678
    OpenUrlCrossRefPubMed
  16. ↵
    1. Sterling RK,
    2. Lissen E,
    3. Clumeck N,
    4. Sola R,
    5. Correa MC,
    6. Montaner J,
    7. S Sulkowski M,
    8. Torriani FJ,
    9. Dieterich DT,
    10. Thomas DL,
    11. Messinger D,
    12. Nelson M
    and APRICOT Clinical Investigators: Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43(6): 1317-1325, 2006. PMID: 16729309. DOI: 10.1002/hep.21178
    OpenUrlCrossRefPubMed
  17. ↵
    1. Enomoto H,
    2. Ueno Y,
    3. Hiasa Y,
    4. Nishikawa H,
    5. Hige S,
    6. Takikawa Y,
    7. Taniai M,
    8. Ishikawa T,
    9. Yasui K,
    10. Takaki A,
    11. Takaguchi K,
    12. Ido A,
    13. Kurosaki M,
    14. Kanto T,
    15. Nishiguchi S
    and Japan Etiology of Liver Cirrhosis Study Group in the 54th Annual Meeting of JSH: The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan. J Gastroenterol 56(2): 158-167, 2021. PMID: 33219410. DOI: 10.1007/s00535-020-01748-x
    OpenUrlCrossRefPubMed
  18. ↵
    1. Kamada T,
    2. Ohdaira H,
    3. Ito E,
    4. Fuse Y,
    5. Takahashi J,
    6. Nakashima K,
    7. Nakaseko Y,
    8. Yoshida M,
    9. Eto K and
    10. Suzuki Y
    : Preoperative masseter muscle sarcopenia predicts mortality in patients with oesophageal cancer. Anticancer Res 42(1): 301-310, 2022. PMID: 34969738. DOI: 10.21873/anticanres.15486
    OpenUrlAbstract/FREE Full Text
    1. Tandon P,
    2. Montano-Loza AJ,
    3. Lai JC,
    4. Dasarathy S and
    5. Merli M
    : Sarcopenia and frailty in decompensated cirrhosis. J Hepatol 75 Suppl 1: S147-S162, 2021. PMID: 34039486. DOI: 10.1016/j.jhep.2021.01.025
    OpenUrlCrossRefPubMed
    1. Omiya S,
    2. Komatsu S,
    3. Kido M,
    4. Kuramitsu K,
    5. Gon H,
    6. Fukushima K,
    7. Urade T,
    8. So S,
    9. Sofue K,
    10. Yano Y,
    11. Sakai Y,
    12. Yanagimoto H,
    13. Toyama H,
    14. Ajiki T and
    15. Fukumoto T
    : Impact of sarcopenia as a prognostic factor on reductive hepatectomy for advanced hepatocellular carcinoma. Anticancer Res 41(11): 5775-5783, 2021. PMID: 34732451. DOI: 10.21873/anticanres.15394
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Nishikawa H,
    2. Yoh K,
    3. Enomoto H,
    4. Ikeda N,
    5. Takashima T,
    6. Aizawa N,
    7. Nishimura T,
    8. Nishiguchi S and
    9. Iijima H
    : Predictors for grip strength loss in patients with chronic liver diseases. In Vivo 35(1): 363-371, 2021. PMID: 33402485. DOI: 10.21873/invivo.12267
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Younossi ZM,
    2. Stepanova M,
    3. Jacobson I,
    4. Muir AJ,
    5. Pol S,
    6. Zeuzem S,
    7. Younes Z,
    8. Herring R,
    9. Lawitz E,
    10. Younossi I and
    11. Racila A
    : Not achieving sustained viral eradication of hepatitis C virus after treatment leads to worsening patient-reported outcomes. Clin Infect Dis 70(4): 628-632, 2020. PMID: 30949674. DOI: 10.1093/cid/ciz243
    OpenUrlCrossRefPubMed
  21. ↵
    1. Divella R,
    2. DE Palma G,
    3. Tufaro A,
    4. Pelagio G,
    5. Gadaleta-Caldarola G,
    6. Bringiotti R and
    7. Paradiso A
    : Diet, probiotics and physical activity: the right allies for a healthy microbiota. Anticancer Res 41(6): 2759-2772, 2021. PMID: 34083266. DOI: 10.21873/anticanres.15057
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Schlevogt B,
    2. Boeker KHW,
    3. Mauss S,
    4. Klinker H,
    5. Heyne R,
    6. Link R,
    7. Simon KG,
    8. Sarrazin C,
    9. Serfert Y,
    10. Manns MP and
    11. Wedemeyer H
    : Weight gain after interferon-free treatment of chronic hepatitis C-Results from the German hepatitis C-registry (DHC-R). Biomedicines 9(10): 1495, 2021. PMID: 34680612. DOI: 10.3390/biomedicines9101495
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

In Vivo: 36 (3)
In Vivo
Vol. 36, Issue 3
May-June 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Possible Alterations in Appetite-related Molecules After the Elimination of Hepatitis C Virus
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
8 + 7 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Possible Alterations in Appetite-related Molecules After the Elimination of Hepatitis C Virus
YOSHIHIRO SHIMONO, HIRAYUKI ENOMOTO, NOBUHIRO AIZAWA, TOMOYUKI TAKASHIMA, NAOTO IKEDA, YUKIHISA YURI, AOI FUJIWARA, KOHEI YOSHIHARA, RYOTA YOSHIOKA, SHOKI KAWATA, SHOGO OTA, RYOTA NAKANO, HIDEYUKI SHIOMI, TAKASHI NISHIMURA, HIROKO IIJIMA
In Vivo May 2022, 36 (3) 1491-1496; DOI: 10.21873/invivo.12856

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Possible Alterations in Appetite-related Molecules After the Elimination of Hepatitis C Virus
YOSHIHIRO SHIMONO, HIRAYUKI ENOMOTO, NOBUHIRO AIZAWA, TOMOYUKI TAKASHIMA, NAOTO IKEDA, YUKIHISA YURI, AOI FUJIWARA, KOHEI YOSHIHARA, RYOTA YOSHIOKA, SHOKI KAWATA, SHOGO OTA, RYOTA NAKANO, HIDEYUKI SHIOMI, TAKASHI NISHIMURA, HIROKO IIJIMA
In Vivo May 2022, 36 (3) 1491-1496; DOI: 10.21873/invivo.12856
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Evaluation of Medication Instruction Sheets for Patients Undergoing R-CHOP Therapy in Non-Hodgkin’s Lymphoma
  • Modification of the ALBI-PLT Score for the Prediction of High-risk Varices
  • Prospective Exploratory Study of the Relationship Between Radiation Pneumonitis and TGF-β1 in Exhaled Breath Condensate
Show more Clinical Studies

Similar Articles

Keywords

  • Chronic hepatitis C
  • direct acting antiviral
  • sustained viral response
  • appetite-related hormones
In Vivo

© 2022 In Vivo

Powered by HighWire